Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates


In Advanced Renal Cell Carcinoma


Pazopanib is an orally administered, multi-tyrosine kinase inhibitor that interrupts tumor growth in renal cell carcinoma.

In a randomized, double-blind, placebo-controlled, multinational trial in patients with locally advanced or metastatic renal cell carcinoma, the median progression-free survival (PFS) of patients who were treated with pazopanib 800 mg once daily was significantly longer than that of placebo recipients (9.2 vs 4.2 months; hazard ratio 0.46 [95% CI 0.34, 0.62]).

In prespecified analyses in treatment-naive and cytokine-pretreated patients, grouped according to prior treatment history, age, sex, Memorial Sloan-Kettering Cancer Center risk category, and Eastern Cooperative Oncology Group performance status, median PFS was significantly longer in pazopanib than placebo recipients in all subgroups.

Pazopanib recipients also had a significantly higher overall response rate than placebo recipients; in pazopanib recipients, the median time to response was 11.9 weeks and the median duration of response was 58.7 weeks.

Oral pazopanib had an acceptable tolerability profile in patients with advanced renal cell carcinoma. Adverse events were common in pazopanib and placebo recipients and were mostly of mild to moderate severity.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


  1. 1.

    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996 Sep 19; 335(12): 865–75

  2. 2.

    Chow W-H, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14(5): 288–301

  3. 3.

    Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2009 May; 20Suppl. 4: iv81–2

  4. 4.

    Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009 Dec; 104(11): 1585–9

  5. 5.

    Brugarolas J. Renal-cell carcinoma: molecular pathways and therapies. N Engl J Med 2007 Jan 11; 356(2): 185–7

  6. 6.

    Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010 Jan; 9(1): 17–8

  7. 7.

    Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Cancer Netw 2009 Jun; 7(6): 618–30

  8. 8.

    National Comprehensive Cancer Network. Clinical practice guidelines in oncology: kidney cancer [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf [Accessed 2010 Apr 20]

  9. 9.

    Ljungberg B, Cowan N, Hanbury DC, et al. Guidelines on renal cell carcinoma. European Association of Urology [online]. Available from URL: http://www.uroweb.org/gls/pdf/Renal%20Cell%20Carcinoma%202010.pdf [Accessed 2010 Jun 16]

  10. 10.

    GlaxoSmithKline. Votrient (pazopanib): prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf [Accessed 2010 Apr 20]

  11. 11.

    European Medicines Agency. Votrient (pazopanib): summary of product characteristics [online]. Available from URL:http://www.nelm.nhs.uk/en/Original-search/?query=pazopanib [Accessed 2010 Jul 5]

  12. 12.

    Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009 Nov 17; 101(10): 1717–23

  13. 13.

    FDA Centre for Drug Evaluation and Research. Votrient (pazopanib): summary review [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009022465s000SumR.pdf [Accessed 2010 Mar 21]

  14. 14.

    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010 Feb 20; 28(6): 1061–8

  15. 15.

    Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010 Jan 20; 28(3): 475–80

  16. 16.

    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 Feb 2; 92(3): 205–16

  17. 17.

    Hutson TE, Davis ID, Machiels JP, et al. Predictive and prognostic factors in phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract no. 5780 plus oral presentation]. 33rd Congress of the European Society for Medical Oncology; 2008 Sep 12–16; Stockholm

  18. 18.

    Heymach JV, Tran HT, Fritsche HA, et al. Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib [abstract no. A11 with poster]. 21st American Association for Cancer Research —National Cancer Institute — European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15–19; Boston (MA)

  19. 19.

    National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [Accessed 2010 Apr 29]

  20. 20.

    Xu C, Reck B, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism [abstract no. P-1114]. 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology; 2009 Sep 20–24; Berlin

  21. 21.

    GlaxoSmithKline. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [ClinicalTrials. gov identifier NCT00720941]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=NCT00720941 [Accessed 2010 May 4]

  22. 22.

    GlaxoSmithKline. Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES) [ClinicalTrials.gov identifier NCT01064310]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=NCT01064310 [Accessed 2010 Jun 16]

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: N. Agarwal, Division of Hematology and Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA; R. Iacovelli, Oncology Unit, Department of Radiology, Oncology and Human Pathology, “Sapienza” University of Rome, Rome, Italy; A.A.M. van der Veldt, Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, the Netherlands.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from any comments received were made on the basis of scientific and editorial merit.

Author information

Correspondence to Mark Sanford.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sanford, M., Keating, G.M. Pazopanib. BioDrugs 24, 279–286 (2010). https://doi.org/10.2165/11205480-000000000-00000

Download citation


  • Renal Cell Carcinoma
  • Sorafenib
  • Sunitinib
  • Placebo Recipient
  • Objective Response Rate